company background image
IDT

IDT AustraliaASX:IDT Stock Report

Market Cap

AU$147.5m

7D

-7.2%

1Y

286.7%

Updated

18 Oct, 2021

Data

Company Financials
IDT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

IDT Overview

IDT Australia Limited researches, develops, manufactures, and sells active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for IDT Australia
Historical stock prices
Current Share PriceAU$0.58
52 Week HighAU$0.15
52 Week LowAU$0.76
Beta0.46
1 Month Change-1.70%
3 Month Change78.46%
1 Year Change286.67%
3 Year Change262.50%
5 Year Change176.19%
Change since IPO271.25%

Recent News & Updates

Aug 31
IDT Australia's (ASX:IDT) Promising Earnings May Rest On Soft Foundations

IDT Australia's (ASX:IDT) Promising Earnings May Rest On Soft Foundations

Investors were disappointed with IDT Australia Limited's ( ASX:IDT ) earnings, despite the strong profit numbers. We...

Mar 20
Is IDT Australia's (ASX:IDT) 280% Share Price Increase Well Justified?

Is IDT Australia's (ASX:IDT) 280% Share Price Increase Well Justified?

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

Jan 13
IDT Australia (ASX:IDT) Is In A Good Position To Deliver On Growth Plans

IDT Australia (ASX:IDT) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Dec 09
Does IDT Australia's (ASX:IDT) CEO Salary Compare Well With The Performance Of The Company?

Does IDT Australia's (ASX:IDT) CEO Salary Compare Well With The Performance Of The Company?

David Sparling has been the CEO of IDT Australia Limited ( ASX:IDT ) since 2018, and this article will examine the...

Shareholder Returns

IDTAU PharmaceuticalsAU Market
7D-7.2%0.04%0.9%
1Y286.7%-2.4%20.2%

Return vs Industry: IDT exceeded the Australian Pharmaceuticals industry which returned -2.4% over the past year.

Return vs Market: IDT exceeded the Australian Market which returned 20.2% over the past year.

Price Volatility

Is IDT's price volatile compared to industry and market?
IDT volatility
IDT Beta0.46
Industry Beta1.3
Market Beta1

Stable Share Price: IDT is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: IDT's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1975n/aDavid Sparlinghttps://en.idtaus.com.au

IDT Australia Limited researches, develops, manufactures, and sells active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. The company offers analytical method development, stability chambers, and chemistry and microbiology quality control laboratory services. Its services also include project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs, as well as pharmaceutical development services in all dosage forms.

IDT Australia Fundamentals Summary

How do IDT Australia's earnings and revenue compare to its market cap?
IDT fundamental statistics
Market CapAU$147.51m
Earnings (TTM)AU$2.10m
Revenue (TTM)AU$16.93m

66.2x

P/E Ratio

8.2x

P/S Ratio

Valuation

Is IDT Australia undervalued compared to its fair value and its price relative to the market?

66.21x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IDT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IDT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IDT is poor value based on its PE Ratio (66.2x) compared to the Oceanic Pharmaceuticals industry average (45x).

PE vs Market: IDT is poor value based on its PE Ratio (66.2x) compared to the Australian market (19.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IDT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IDT is overvalued based on its PB Ratio (5x) compared to the AU Pharmaceuticals industry average (3.3x).


Future Growth

How is IDT Australia forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

66.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IDT Australia has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has IDT Australia performed over the past 5 years?

37.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IDT has high quality earnings.

Growing Profit Margin: IDT became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: IDT has become profitable over the past 5 years, growing earnings by 37.7% per year.

Accelerating Growth: IDT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: IDT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).


Return on Equity

High ROE: IDT's Return on Equity (7.6%) is considered low.


Financial Health

How is IDT Australia's financial position?


Financial Position Analysis

Short Term Liabilities: IDT's short term assets (A$17.3M) exceed its short term liabilities (A$6.1M).

Long Term Liabilities: IDT's short term assets (A$17.3M) exceed its long term liabilities (A$445.0K).


Debt to Equity History and Analysis

Debt Level: IDT's debt to equity ratio (2.8%) is considered satisfactory.

Reducing Debt: IDT's debt to equity ratio has reduced from 5.8% to 2.8% over the past 5 years.

Debt Coverage: IDT's debt is well covered by operating cash flow (48.3%).

Interest Coverage: IDT's interest payments on its debt are well covered by EBIT (62.3x coverage).


Balance Sheet


Dividend

What is IDT Australia current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IDT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IDT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IDT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IDT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: IDT is not paying a notable dividend for the Australian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IDT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

David Sparling

3.67yrs

Tenure

AU$600,496

Compensation

Dr. David Sparling, BVSc (Hons), LLB (Hons), GDipAppCGov, has been the Chief Executive Officer at IDT Australia Limited since July 2018 and previously served as its Interim Chief Executive Officer since Fe...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD445.70K) is above average for companies of similar size in the Australian market ($USD302.72K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: IDT's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: IDT's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

IDT Australia Limited's employee growth, exchange listings and data sources


Key Information

  • Name: IDT Australia Limited
  • Ticker: IDT
  • Exchange: ASX
  • Founded: 1975
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$147.514m
  • Shares outstanding: 239.86m
  • Website: https://en.idtaus.com.au

Location

  • IDT Australia Limited
  • 45 Wadhurst Drive
  • Boronia
  • Victoria
  • 3155
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 07:04
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.